What is PegBio?
Established in 2008, PegBio is dedicated to the research and development of novel treatments for chronic diseases, with a particular focus on endocrine and metabolic disorders. The company leverages its proprietary HECTOR technology system to discover and screen innovative molecular entities, including peptide drugs, protein drugs, and small molecules. PegBio's robust R&D capabilities and experienced team are geared towards tackling significant market opportunities in areas such as type 2 diabetes, obesity, and metabolic dysfunction-related conditions, positioning it as a key player in the biopharmaceutical innovation landscape.
How much funding has PegBio raised?
PegBio has raised a total of $145M across 4 funding rounds:
Series A
$2M
Series C
$1M
Series E
$20M
Other Financing Round
$122M
Series A (2011): $2M with participation from Legend Star
Series C (2015): $1M led by Oriza Seed Capital and Mingxin China Growth Fund
Series E (2017): $20M, investors not publicly disclosed
Other Financing Round (2020): $122M featuring YuanBio Venture Capital, Zhongxin Huihai Investment Fund Management, Yunfeng Capital, Yuanfeng Capital, Qianhai FoF, TF Capital, and Yingke PE
Key Investors in PegBio
Legend Star
Legend Star is an investment firm that likely focuses on technology and innovation, given its name and domain, potentially supporting companies with disruptive technologies in the biotech space.
Mingxin China Growth Fund
Mingxin China Growth Fund is a venture capital firm specializing in growth and expansion stage investments, particularly in China, with a broad sector focus including healthcare and biotech.
Yunfeng Capital
Yunfeng Capital is a prominent investment firm that provides not only capital but also strategic guidance, focusing on nurturing future industry leaders across sectors including technology and healthcare.
What's next for PegBio?
With its latest major strategic investment and a history of significant capital infusions, PegBio is poised for accelerated growth and the advancement of its product pipeline. The company's focus on chronic disease therapies, supported by its unique HECTOR technology, suggests a strategic direction towards clinical validation and potential commercialization. Future endeavors will likely involve expanding its research initiatives, forging strategic partnerships, and navigating the complex regulatory pathways to bring its innovative treatments to patients worldwide. The sustained investor confidence indicates a strong belief in PegBio's long-term vision and its capacity to deliver impactful solutions in the biopharmaceutical sector.
See full PegBio company page
